OTCMKTS:TRLPF Acerus Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.21 0.00 (0.00%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$2.21▼$2.2150-Day Range$0.02▼$4.2552-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$571.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsHeadlines Acerus Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.41 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Acerus Pharmaceuticals. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for TRLPF. Previous Next 0.0 Dividend Strength Dividend YieldAcerus Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcerus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRLPF. Previous Next 2.0 News and Social Media Coverage News SentimentAcerus Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Acerus Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acerus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.02% of the stock of Acerus Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Acerus Pharmaceuticals (OTCMKTS:TRLPF) StockAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More TRLPF Stock News HeadlinesJune 29, 2022 | americanbankingnews.comAcerus Pharmaceuticals (OTCMKTS:TRLPF) Share Price Crosses Above Two Hundred Day Moving Average of $0.89October 27, 2020 | businesswire.comAcerus to Report Third Quarter 2020 Financial Results and Host Investor CallSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:TRLPF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year FoundedN/ACompany Calendar Last Earnings11/05/2018Today7/05/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,790,000.00 Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales77.44 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$571.54 million OptionableNot Optionable Beta2.52 Acerus Pharmaceuticals Frequently Asked Questions How has Acerus Pharmaceuticals' stock performed in 2022? Acerus Pharmaceuticals' stock was trading at $0.0203 at the start of the year. Since then, TRLPF stock has increased by 10,786.7% and is now trading at $2.21. View the best growth stocks for 2022 here. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) issued its quarterly earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%. View Acerus Pharmaceuticals' earnings history. Who are Acerus Pharmaceuticals' key executives? Acerus Pharmaceuticals' management team includes the following people: Ms. Patricia Symmes, Chief Operating OfficerDr. Nathan Bryson, Chief Scientific OfficerMr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.Mr. Edward Gudaitis, Pres , CEO & DirectorMr. Robert M. Motz, Chief Financial Officer Who are some of Acerus Pharmaceuticals' key competitors? Some companies that are related to Acerus Pharmaceuticals include Global Blood Therapeutics (GBT), Schrödinger (SDGR), Arcus Biosciences (RCUS), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), Xencor (XNCR), OPKO Health (OPK), Dynavax Technologies (DVAX), Aurinia Pharmaceuticals (AUPH), Amphastar Pharmaceuticals (AMPH), Xenon Pharmaceuticals (XENE), Cryoport (CYRX), Emergent BioSolutions (EBS) and Ligand Pharmaceuticals (LGND). View all of TRLPF's competitors. What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF." How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acerus Pharmaceuticals' stock price today? One share of TRLPF stock can currently be purchased for approximately $2.21. How much money does Acerus Pharmaceuticals make? Acerus Pharmaceuticals (OTCMKTS:TRLPF) has a market capitalization of $571.54 million and generates $7.38 million in revenue each year. How many employees does Acerus Pharmaceuticals have? Acerus Pharmaceuticals employs 29 workers across the globe. How can I contact Acerus Pharmaceuticals? Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for Acerus Pharmaceuticals is www.aceruspharma.com. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at ir@aceruspharma.com. This page (OTCMKTS:TRLPF) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here